STOCK MARKET BSE NSE

Aurobindo Pharma launches COVID-19 drug Molnupiravir in India

Molnupiravir is for treatment of adult patients hospitalised with COVID-19, under certain conditions, a press release from the city-based drug maker said.

Published: 06th January 2022 11:22 AM  |   Last Updated: 06th January 2022 11:22 AM   |  A+A-

Experimental antiviral pill Molnupiravir

Antiviral drug Molnupiravir. (File photo| AFP)

By PTI

HYDERABAD: Aurobindo Pharma Limited has launched COVID-19 treatment drug Molnupiravir under brand name "Molnaflu" in India.

Molnupiravir is for treatment of adult patients hospitalised with COVID-19, under certain conditions, a press release from the city-based drug maker said.

Molnupiravir was earlier approved under Emergency Use Authorisation from the Central Drugs Standard Control Organisation.

Earlier last year, Aurobindo had signed a bi-lateral non-exclusive voluntary licensing agreement with Merck Sharpe Dohme, Singapore (MSD), a subsidiary of Merck & Co.

(US) to manufacture and supply Molnupiravir to over 100 low and middle-income countries (LMIC), including India.

K Nithyananda Reddy, Vice Chairman and Managing Director, Aurobindo said, "We are delighted with the timely permission from DCGI for the licensed version of Molnupiravir (Molnaflu) as it opens up access to an affordable treatment option for COVID-19 patients and enable us to help battle the pandemic with effective and high-quality pharmaceutical products”.

For the licensed version of Molnupiravir, Aurobindo enjoys backward integration with in-house API (active pharmaceutical ingredient) manufacturing which equips it with stronger control on the Quality systems and Supply chain.

The product will be made at the Company's manufacturing facilities in India that are approved by global regulatory agencies including USFDA and UK MHRA.

The company has adequate capacities to meet the global demand across the over 100 LMI Countries for the product, Aurobindo said.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp